Chimerna Therapeutics, Inc. was awarded a $302,605 project grant from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) to develop a scalable, low-cost method for semi-synthesis of site-specifically labeled circular RNAs. The key objectives are to: 1) optimize a bacterial strain and expression conditions for high efficiency amino functionalization of circular RNAs, and 2) improve the endosomal escape of RNAs by site-specific lipid conjugation. This work leverages Chimerna's proprietary technology for producing high-purity circular RNAs and aims to overcome challenges in RNA therapeutics delivery, such as poor endosomal escape. The 12-month project period runs from February 1, 2025 to January 31, 2026.
Generated 3/4/25, 4:25 AM